Table 2.

Hazard Ratios for the Primary, Secondary, and Exploratory End Points, According to Randomized Assignment to Vitamin D or Placebo, in Intention-to-Treat Analyses.^*

End Point	Vitamin D Group (N = 12,927)	Placebo Group (N = 12,944)	Hazard Ratio (95% CI)
	no. of participants with event
Primary end points: confirmed incident fractures
Total	769	782	0.98 (0.89–1.08)
Nonvertebral	721	744	0.97 (0.87–1.07)
Hip	57	56	1.01 (0.70–1.47)
Secondary end points: confirmed incident fractures excluding toe, finger, skull, periprosthetic, and pathologic fractures
Total	678	685	0.99 (0.89–1.10)
Nonvertebral	630	649	0.97 (0.87–1.08)
Hip	54	52	1.03 (0.70–1.52)
Exploratory end points: confirmed incident fractures excluding periprosthetic and pathologic fractures
Major osteoporotic fractures: hip, wrist, humerus, or clinical spine fractures	276	278	0.99 (0.83–1.17)
Pelvic	32	29	1.08 (0.64–1.80)
Wrist	118	132	0.89 (0.69–1.15)

^*Analyses were performed with the use of Cox proportional-hazards models that were adjusted for age, sex, race or ethnic group, and n–3 fatty acid randomization group. Confidence intervals were not adjusted for multiple comparisons, and inferences drawn from them may not be reproducible.